Bill Text: IL HB4628 | 2023-2024 | 103rd General Assembly | Introduced
Bill Title: Amends the Illinois Controlled Substances Act. Schedules Tianeptine as a Schedule III controlled substance.
Spectrum: Slight Partisan Bill (Republican 3-1)
Status: (Introduced) 2024-04-19 - House Floor Amendment No. 1 Rule 19(c) / Re-referred to Rules Committee [HB4628 Detail]
Download: Illinois-2023-HB4628-Introduced.html
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
1 | AN ACT concerning criminal law.
| |||||||||||||||||||
2 | Be it enacted by the People of the State of Illinois, | |||||||||||||||||||
3 | represented in the General Assembly:
| |||||||||||||||||||
4 | Section 5. The Illinois Controlled Substances Act is | |||||||||||||||||||
5 | amended by changing Section 208 as follows:
| |||||||||||||||||||
6 | (720 ILCS 570/208) (from Ch. 56 1/2, par. 1208) | |||||||||||||||||||
7 | Sec. 208. (a) The controlled substances listed in this | |||||||||||||||||||
8 | Section are included in Schedule III. | |||||||||||||||||||
9 | (b) Unless specifically excepted or unless listed in | |||||||||||||||||||
10 | another schedule, any material, compound, mixture, or | |||||||||||||||||||
11 | preparation which contains any quantity of the following | |||||||||||||||||||
12 | substances having a stimulant effect on the central nervous | |||||||||||||||||||
13 | system, including its salts, isomers (whether optical | |||||||||||||||||||
14 | position, or geometric), and salts of such isomers whenever | |||||||||||||||||||
15 | the existence of such salts, isomers, and salts of isomers is | |||||||||||||||||||
16 | possible within the specific chemical designation; | |||||||||||||||||||
17 | (1) Those compounds, mixtures, or preparations in | |||||||||||||||||||
18 | dosage unit form containing any stimulant substances | |||||||||||||||||||
19 | listed in Schedule II which compounds, mixtures, or | |||||||||||||||||||
20 | preparations were listed on August 25, 1971, as excepted | |||||||||||||||||||
21 | compounds under Title 21, Code of Federal Regulations, | |||||||||||||||||||
22 | Section 308.32, and any other drug of the quantitative | |||||||||||||||||||
23 | composition shown in that list for those drugs or which is |
| |||||||
| |||||||
1 | the same except that it contains a lesser quantity of | ||||||
2 | controlled substances; | ||||||
3 | (2) Benzphetamine; | ||||||
4 | (3) Chlorphentermine; | ||||||
5 | (4) Clortermine; | ||||||
6 | (5) Phendimetrazine ; . | ||||||
7 | (6) Tianeptine. | ||||||
8 | (c) Unless specifically excepted or unless listed in | ||||||
9 | another schedule, any material, compound, mixture, or | ||||||
10 | preparation which contains any quantity of the following | ||||||
11 | substances having a potential for abuse associated with a | ||||||
12 | depressant effect on the central nervous system: | ||||||
13 | (1) Any compound, mixture, or preparation containing | ||||||
14 | amobarbital, secobarbital, pentobarbital or any salt | ||||||
15 | thereof and one or more other active medicinal ingredients | ||||||
16 | which are not listed in any schedule; | ||||||
17 | (2) Any suppository dosage form containing | ||||||
18 | amobarbital, secobarbital, pentobarbital or any salt of | ||||||
19 | any of these drugs and approved by the Federal Food and | ||||||
20 | Drug Administration for marketing only as a suppository; | ||||||
21 | (3) Any substance which contains any quantity of a | ||||||
22 | derivative of barbituric acid, or any salt thereof: | ||||||
23 | (3.1) Aprobarbital; | ||||||
24 | (3.2) Butabarbital (secbutabarbital); | ||||||
25 | (3.3) Butalbital; | ||||||
26 | (3.4) Butobarbital (butethal); |
| |||||||
| |||||||
1 | (4) Chlorhexadol; | ||||||
2 | (5) Methyprylon; | ||||||
3 | (6) Sulfondiethylmethane; | ||||||
4 | (7) Sulfonethylmethane; | ||||||
5 | (8) Sulfonmethane; | ||||||
6 | (9) Lysergic acid; | ||||||
7 | (10) Lysergic acid amide; | ||||||
8 | (10.1) Tiletamine or zolazepam or both, or any salt of | ||||||
9 | either of them. | ||||||
10 | Some trade or other names for a tiletamine-zolazepam
| ||||||
11 | combination product: Telazol.
| ||||||
12 | Some trade or other names for Tiletamine:
| ||||||
13 | 2-(ethylamino)-2-(2-thienyl)-cyclohexanone.
| ||||||
14 | Some trade or other names for zolazepam:
| ||||||
15 | 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-
| ||||||
16 | [3,4-e], [1,4]-diazepin-7(1H)-one, and flupyrazapon. | ||||||
17 | (11) Any material, compound, mixture or preparation | ||||||
18 | containing not more than 12.5 milligrams of pentazocine or | ||||||
19 | any of its salts, per 325 milligrams of aspirin; | ||||||
20 | (12) Any material, compound, mixture or preparation | ||||||
21 | containing not more than 12.5 milligrams of pentazocine or | ||||||
22 | any of its salts, per 325 milligrams of acetaminophen; | ||||||
23 | (13) Any material, compound, mixture or preparation | ||||||
24 | containing not more than 50 milligrams of pentazocine or | ||||||
25 | any of its salts plus naloxone HCl USP 0.5 milligrams, per | ||||||
26 | dosage unit; |
| |||||||
| |||||||
1 | (14) Ketamine; | ||||||
2 | (15) Thiopental. | ||||||
3 | (d) Nalorphine. | ||||||
4 | (d.5) Buprenorphine. | ||||||
5 | (e) Unless specifically excepted or unless listed in | ||||||
6 | another schedule, any material, compound, mixture, or | ||||||
7 | preparation containing limited quantities of any of the | ||||||
8 | following narcotic drugs, or their salts calculated as the | ||||||
9 | free anhydrous base or alkaloid, as set forth below: | ||||||
10 | (1) not more than 1.8 grams of codeine per 100 | ||||||
11 | milliliters or not more than 90 milligrams per dosage | ||||||
12 | unit, with an equal or greater quantity of an isoquinoline | ||||||
13 | alkaloid of opium; | ||||||
14 | (2) not more than 1.8 grams of codeine per 100 | ||||||
15 | milliliters or not more than 90 milligrams per dosage | ||||||
16 | unit, with one or more active non-narcotic ingredients in | ||||||
17 | recognized therapeutic amounts; | ||||||
18 | (3) (blank); | ||||||
19 | (4) (blank); | ||||||
20 | (5) not more than 1.8 grams of dihydrocodeine per 100 | ||||||
21 | milliliters or not more than 90 milligrams per dosage | ||||||
22 | unit, with one or more active, non-narcotic ingredients in | ||||||
23 | recognized therapeutic amounts; | ||||||
24 | (6) not more than 300 milligrams of ethylmorphine per | ||||||
25 | 100 milliliters or not more than 15 milligrams per dosage | ||||||
26 | unit, with one or more active, non-narcotic ingredients in |
| |||||||
| |||||||
1 | recognized therapeutic amounts; | ||||||
2 | (7) not more than 500 milligrams of opium per 100 | ||||||
3 | milliliters or per 100 grams, or not more than 25 | ||||||
4 | milligrams per dosage unit, with one or more active, | ||||||
5 | non-narcotic ingredients in recognized therapeutic | ||||||
6 | amounts; | ||||||
7 | (8) not more than 50 milligrams of morphine per 100 | ||||||
8 | milliliters or per 100 grams with one or more active, | ||||||
9 | non-narcotic ingredients in recognized therapeutic | ||||||
10 | amounts. | ||||||
11 | (f) Anabolic steroids, except the following anabolic | ||||||
12 | steroids that are exempt: | ||||||
13 | (1) Androgyn L.A.; | ||||||
14 | (2) Andro-Estro 90-4; | ||||||
15 | (3) depANDROGYN; | ||||||
16 | (4) DEPO-T.E.; | ||||||
17 | (5) depTESTROGEN; | ||||||
18 | (6) Duomone; | ||||||
19 | (7) DURATESTRIN; | ||||||
20 | (8) DUO-SPAN II; | ||||||
21 | (9) Estratest; | ||||||
22 | (10) Estratest H.S.; | ||||||
23 | (11) PAN ESTRA TEST; | ||||||
24 | (12) Premarin with Methyltestosterone; | ||||||
25 | (13) TEST-ESTRO Cypionates; | ||||||
26 | (14) Testosterone Cyp 50 Estradiol Cyp 2; |
| |||||||
| |||||||